Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as as opposed with imatinib, for the 1st-line procedure of CML-CP. 5 hundred and nineteen individuals with freshly diagnosed CML-CP were being randomly assigned to get dasatinib in a dose of a hundred mg when day by day (259 https://katee186vae9.wikicorrespondence.com/user